TrialJournal of surgical oncology2009

Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665.

Burton L Eisenberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.